Literature DB >> 8410058

Posterior uveitis, paraneoplastic encephalomyelitis and auto-antibodies reacting with developmental protein of brain and retina.

J C Antoine1, J Honnorat, C Vocanson, F Koenig, M Aguera, M F Belin, D Michel.   

Abstract

We report a 68-year-old woman who presented with posterior uveitis, cerebellar ataxia, dysautonomia, peripheral neuropathy and undifferentiated carcinoma. Autopsy showed slight brain inflammatory changes and severe Purkinje cell degeneration. By immunocytochemistry, the serum and CSF contained antibodies that reacted with the cytoplasm of cells in the brain and retina of rat. Some neurons and glial cells were stained. However, the most labelled cells were immature cells of the subventricular layers of the dentate gyrus, olfactory bulb and lateral ventricles. In rat retina, the plexiform layers and cells of the inner granular layer were stained. E15 rat embryo showed diffuse staining of post-mitotic cells and process in the central and peripheral nervous system. With the patient's IgG, various bands of 45, 60, 70 and 135 kDa apparent molecular weight were demonstrated on immunoblots of adult human, adult and E15 embryonic rat brain and rat and bovine retina. Eluates of tissue bound IgG labelled the same bands.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8410058     DOI: 10.1016/0022-510x(93)90176-y

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  12 in total

Review 1.  Anti-CV2 autoantibodies and paraneoplastic neurological syndromes.

Authors:  V Rogemond; J Honnorat
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

Review 2.  Paraneoplastic syndromes of the CNS.

Authors:  Josep Dalmau; Myrna R Rosenfeld
Journal:  Lancet Neurol       Date:  2008-04       Impact factor: 44.182

3.  Paraneoplastic cerebellar degeneration with anti-CV2/CRMP5 antibodies and prostate adenocarcinoma.

Authors:  A Aliprandi; A Terruzzi; A Rigamonti; E Bazzigaluppi; L Tremolizzo; C Ferrarese; A Salmaggi
Journal:  Neurol Sci       Date:  2015-02-17       Impact factor: 3.307

4.  Current approaches to the treatment of paraneoplastic encephalitis.

Authors:  Wolfgang Grisold; Bruno Giometto; Roberta Vitaliani; Stefan Oberndorfer
Journal:  Ther Adv Neurol Disord       Date:  2011-07       Impact factor: 6.570

5.  Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies.

Authors:  J C Antoine; J F Mosnier; L Absi; P Convers; J Honnorat; D Michel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-07       Impact factor: 10.154

6.  Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies.

Authors:  J Honnorat; S Cartalat-Carel; D Ricard; J Ph Camdessanche; A F Carpentier; V Rogemond; F Chapuis; M Aguera; E Decullier; A M Duchemin; F Graus; J C Antoine
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-10-17       Impact factor: 10.154

7.  Limbic encephalitis and immunological perturbations in two patients with thymoma.

Authors:  J C Antoine; J Honnorat; C T Anterion; M Aguera; L Absi; P Fournel; D Michel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-06       Impact factor: 10.154

8.  Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes.

Authors:  J Honnorat; J C Antoine; E Derrington; M Aguera; M F Belin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

Review 9.  Optic neuropathy in cancer patients. Report of a case possibly related to 5 fluorouracil toxicity and review of the literature.

Authors:  L Delval; J Klastersky
Journal:  J Neurooncol       Date:  2002-11       Impact factor: 4.130

Review 10.  Collapsin response mediator proteins (CRMPs): involvement in nervous system development and adult neurodegenerative disorders.

Authors:  Emmanuelle Charrier; Sophie Reibel; Véronique Rogemond; Michèle Aguera; Nicole Thomasset; Jérôme Honnorat
Journal:  Mol Neurobiol       Date:  2003-08       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.